Compounded Tirzepatide: What the FDA Rules Now Say

Compounded tirzepatide was never a generic. It existed because of a specific, temporary legal opening — and that opening closed in early 2025, before most people noticed.

Everything below is dated, because this is a status that changes and the dates are the substance of it. Verified against the FDA’s own compounding statement on 24 August 2026.

Why was compounded tirzepatide legal at all?

Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounders may generally not make copies of an approved drug. There is an exception when the drug is on the FDA’s drug shortage list.

Tirzepatide had been in shortage since 2022 on increased demand. That listing — not a judgment that compounded tirzepatide was safe or equivalent — is what made the compounded market possible.

Remove the shortage, and the legal basis goes with it.

What happened, and when?

Date	What the FDA did
2 Oct 2024	Determined the tirzepatide injection shortage resolved
22 Oct 2024	Decision remanded to the agency for reevaluation as part of litigation
19 Dec 2024	Re-evaluated and issued a new decision: shortage resolved
18 Feb 2025	Enforcement discretion ends for 503A pharmacies and physicians
19 Mar 2025	Enforcement discretion ends for 503B outsourcing facilities

The December decision came with wind-down windows — 60 calendar days for 503A compounders and 90 for 503B — described by the FDA as intended “to avoid unnecessary disruption to patient treatment.” Both have long since passed.

How does this compare with semaglutide?

Tirzepatide went first, and by a clear margin. The FDA set semaglutide’s corresponding timeframes at 22 April 2025 for 503A and 22 May 2025 for 503B.

	Tirzepatide	Semaglutide
Shortage resolved	19 Dec 2024 (reaffirmed)	21 Feb 2025
503A discretion ends	18 Feb 2025	22 Apr 2025
503B discretion ends	19 Mar 2025	22 May 2025

The two drugs are frequently discussed as though they sit in the same regulatory position. They do not, and they never quite did — tirzepatide’s compounded window closed roughly two months earlier at each stage.

The semaglutide side of this is covered in compounded semaglutide: the risks and realities.

So why is it still being sold?

Because the shortage exemption is not the only door, and the remaining doors are narrower than the marketing suggests.

Some sellers describe a product as “personalized” — a different strength, or tirzepatide combined with something else such as a vitamin — on the theory that this makes it not a copy of the approved drug. The FDA has been explicit that it may still act on other grounds regardless, including “findings that a product may be of substandard quality or otherwise unsafe.”

Others are simply operating outside the rules, or selling research-labelled material that was never intended for people at all. That distinction matters more than the price does.

What are the practical risks?

Two, and they are different in kind.

Product risk. A compounded product has not been through FDA review for safety, efficacy, or manufacturing quality. The FDA has raised specific concerns about unapproved GLP-1 products used for weight loss, including salt forms of the active ingredient that are not the same substance as the approved drug.

Administration risk. This one is measurable. Compounded tirzepatide is typically supplied as a vial to be drawn with a separate syringe rather than as a dose-limiting prefilled pen. In a published case series of compounded semaglutide errors, two of three patients administered tenfold doses; the authors named the vial-and-syringe format and unit confusion between millilitres, insulin units, and milligrams as the mechanism. The same format carries the same risk here, and the outcomes are covered in GLP-1 overdose: what the reported cases show.

Frequently asked questions

Is compounded tirzepatide legal?

The shortage-based basis for compounding it ended in early 2025 — 18 February for 503A pharmacies and 19 March for 503B outsourcing facilities. Compounding can still be lawful in narrow circumstances, such as a documented clinical need a patient cannot meet with the approved product, but the broad shortage exemption that created the market is gone.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

No. Approved tirzepatide products have been through FDA review for safety, efficacy, and manufacturing quality. A compounded preparation has not, and its strength, purity, and salt form are not verified by that process.

Why did compounded tirzepatide disappear before compounded semaglutide?

Because the FDA resolved the tirzepatide shortage first. The determination came on 2 October 2024 and was reaffirmed on 19 December 2024, while semaglutide’s came on 21 February 2025 — so each of tirzepatide’s wind-down deadlines fell about two months earlier.

Is compounded tirzepatide cheaper?

Often, which is most of its appeal. Manufacturer self-pay pricing for the approved product has also come down substantially since the compounded market peaked — see GLP-1 cost: what you actually pay.

What should I ask if I am already using it?

The questions worth asking a prescriber are what the product actually contains, what strength, what salt form, and how the dose is measured. If the answer involves drawing from a vial in insulin units, that is the specific setup behind the documented tenfold errors.

The takeaway

Compounded tirzepatide was a product of a shortage, not a policy judgement that it was a good substitute. The shortage ended, the wind-down windows closed in February and March 2025, and the legal footing that supported the market went with them.

That does not mean everything currently sold under the name has vanished — it means the reason it was permitted has. Anyone weighing it now is weighing an unapproved preparation, usually in a format that makes dosing errors easier, against an approved product whose cash price has moved a long way since 2024. That comparison belongs with a prescriber, and regulatory status in this area changes; check the FDA statement below rather than trusting any summary, including this one.

Compounded Tirzepatide: What Changed and What's Left